AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02291510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met XR
Description: metformin extended-release tablets
Study NCT02291510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met IR
Description: metformin immediate-release tablets
Study NCT03049137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant
Study NCT03455023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Description: Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
Study NCT02440100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
Study NCT01601574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers modified program
Description: Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
Study NCT01601574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care group
Description: One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
Study NCT00698568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine- adjuvanted GSK 208141
Description: Intramuscular injection, 3 doses
Study NCT00698568 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 3 doses
Study NCT03385018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach
Description: * Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~* The number of trocars is 6 or less~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Combined organ resection only in cholecystectomy and splenectomy~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection
Study NCT03385018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach
Description: * Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection
Study NCT04950699 — intervention group
Intervention type: GENETIC
Intervention: Single-nucleotide Polymorphism of genes related with Dyslipidemia
Description: This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
Study NCT01314651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Control and Sleep Restriction
Description: 5 instructions in stimulus control and individually-tailored sleep restriction
Study NCT01314651 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Modification
Description: 5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
Study NCT02843568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02843568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02843568 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard fractionation
Description: 60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
Study NCT02843568 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractionation
Description: 60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
Study NCT02843568 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: 40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
Study NCT02843568 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: 40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
Study NCT02843568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Four Dimensional Computed Tomographic Imaging (4DCT)
Description: Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
Study NCT02843568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Dimensional Computed Tomographic Imaging (4DCT)
Description: Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
Study NCT02313142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg exercises
Study NCT03879798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: 100 mg daily
Study NCT03879798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
Study NCT05054335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Undergo walking function assessment with optical motion capture
Study NCT05054335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo bi-plane dynamic X-ray imaging
Study NCT04139317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
Study NCT04139317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
Study NCT04139317 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
Study NCT01023100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550 oral solutions
Description: flavored and unflavored prototype CP-690,550 formulations
Study NCT02440100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
Study NCT02440100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo which will be given as oral suspension, once a day for 14 days
Study NCT03916003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
Study NCT04236349 — intervention group
Intervention type: GENETIC
Intervention: immunogenetics
Description: blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
Study NCT02512718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Comparison of FOLE vs. SOLE
Study NCT02512718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soybean oil lipid emulsion
Description: Comparison of FOLE vs. SOLE
Study NCT00039416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00039416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02580318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breathalyzer
Study NCT03697785 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Beacon Care System
Description: Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
Study NCT02869932 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Lung CT scan
Description: Lung CT scan without injection
Study NCT03697785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Care System
Description: Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
Study NCT03850392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)
Description: cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
Study NCT02493361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02493361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pIL-12
Study NCT04579263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota
Description: Transplantation of fecal microbiota of healthy donor with normal body mass index
Study NCT04059926 — intervention group
Intervention type: OTHER
Intervention: insert apossing lumen metal stent
Description: insert apossing lumen metal stent
Study NCT01260233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Description: Smoking cessation program includes:~* brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~* smoking cessation brochures~* referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~* free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day
Study NCT01490346 — intervention group
Intervention type: DRUG
Intervention: Initiation of anti-retroviral therapy
Description: Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
Study NCT03749551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac magnetic resonance (CMR) post haemodialysis
Description: patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
Study NCT00267007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROCRIT 40,000 IU QW
Description: Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
Study NCT00267007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
Study NCT03373266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: anesthesia was maintained with Sevoflurane 1-2%.
Study NCT03373266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: anesthesia was maintained with isoflurane 1-2%.
Study NCT01614925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain
Description: Periodontal surgery with the additional use of Straumann® Emdogain
Study NCT01614925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Periodontal surgery alone
Study NCT04267016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TruGraf Testing - Peripheral blood gene expression profiling
Description: 5 mL collection PAXgene blood sample
Study NCT03970668 — intervention group
Intervention type: DRUG
Intervention: Linagliptin 5 mg Oral Tablet
Description: Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
Study NCT03970668 — intervention group
Intervention type: DRUG
Intervention: Insulin
Description: Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
Study NCT02438865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate instillation of intravesical chemotherapy-Epirubicin-
Study NCT02438865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintainance therapy of intravesical chemotherapy-Epirubicin-
Study NCT01147016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2Bi-armed activated T cells
Description: Total of 4 of the T cell infusions intravenously over a period of 1 month.
Study NCT01147016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: As prescribed by physician, standard of care.
Study NCT01147016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: As prescribed by physician, standard of care.
Study NCT01147016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: As prescribed by physician, standard of care.
Study NCT01147016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
Study NCT01147016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: As prescribed by physician, standard of care.
Study NCT01147016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: As recommended by physician, post immunotherapy.
Study NCT01882231 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
Description: Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
Study NCT02131337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiology study
Description: after 3 months to check for pulmonary vein isolation (PVI) status
Study NCT02746705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
Study NCT02746705 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
Study NCT02746705 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training Program
Study NCT02746705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training Program
Study NCT02701816 — intervention group
Intervention type: DEVICE
Intervention: innova stent (Boston scientific)
Study NCT00665197 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Protracted Course Radiotherapy
Description: External Beam Radiation 30 Gy in 10 fractions
Study NCT00665197 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Radiotherapy
Description: External Beam Radiation 20 Gy in 5 fractions
Study NCT04067024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia made by surgeon
Description: infiltration with local anesthetics
Study NCT04067024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia group
Description: Pecs block I and Supraclavicular nerf block
Study NCT01406275 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin and clavulanate
Study NCT03147001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
Study NCT03147001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-caloric placebo ingestion
Description: A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
Study NCT00732771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Study NCT01872468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured intervention
Description: Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
Study NCT00971399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: ramosetron 0.1mg q.d. SL on D1-5
Study NCT00971399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron 8mg, b.i.d SL on D1-5
Study NCT00908531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole (Femara)
Description: tablet 2.5 mg daily
Study NCT00908531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole (Femara)
Description: tablet 2.5 mg daily
Study NCT01001663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemoSeal®
Description: Closure device for femoral artery access closure
Study NCT01001663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Conventional manual compression
Study NCT01559961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-1612
Description: Single intravesical 30-minute treatments with escalating doses of TTI-1612.
Study NCT01989650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Break
Description: A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
Study NCT01989650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No break
Description: No break will be provided
Study NCT00511004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Comparing 400 mg to 800 mg dose
Study NCT00511004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Providing diethylcarbamazine more frequently in combination with albendazole
Study NCT01242475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme